Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

被引：0

作者：

Hochster, H. ^{[1
]}

Catalano, Paul J. ^{[2
]}

O'Dwyer, Peter J. ^{[3
]}

Mitchell, Edith P. ^{[4
]}

Cohen, Deirdre Jill ^{[5
,6
]}

Faller, Bryan Andrew ^{[7
]}

Kortmansky, Jeremy S. ^{[8
]}

Kircher, Sheetal Mehta ^{[9
]}

Lacy, Jill ^{[10
]}

Lenz, Heinz-Josef ^{[11
]}

Verma, Udit N. ^{[12
]}

Benson, Al Bowen, III ^{[13
]}

机构：

[1] Rutgers Canc Inst, New Brunswick, NJ USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[5] NYU Perlmutter Canc Ctr, New York, NY USA

[6] ECOG ACRIN, New York, NY USA

[7] Midwest Hem & Onc Assoc, Clayton, MO USA

[8] Med Oncol & Hematol, Hamden, CT USA

[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[10] Yale Univ, Smilow Canc Hosp, New Haven, CT USA

[11] Univ Southern Calif, Los Angeles, CA USA

[12] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[13] Northwestern Med, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O - 030

引用

页数：1

共 38 条

[21] Prospective pharmacogenetic analysis in advanced colorectal cancer (CRC) patients receiving first-line cetuximab-UFT-irinotecan therapy: Importance of gene polymorphisms related to antibody-dependent cellular cytotoxicity (ADCC)
Etienne-Grimaldi, M.
Bennouna, J.
Formento, J.
Douillard, J.
Francoual, M.
Francois, E.
Faroux, R.
El Hannani, C.
Jacob, J.
Milano, G.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[22] WEEKLY EPIRUBICIN VERSUS DOXORUBICIN AS 2ND LINE THERAPY IN ADVANCED BREAST-CANCER - A RANDOMIZED CLINICAL-TRIAL
GASPARINI, G
DALFIOR, S
PANIZZONI, GA
FAVRETTO, S
POZZA, F
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1991, 14 (01): : 38 - 44
[23] A phase II trial of cetuximab/irinotecan every 2 weeks in patients with metastatic colorectal cancer (CRC) that expresses wild-type KRAS after failure to first-line therapy with an irinotecan-containing regimen with or without detectable epidermal growth factor receptor (EGFR) expression.
Hong, Y.
Tang, M.
Kim, S.
Baek, J.
Lee, J.
Chang, H.
Jang, S.
Kang, Y.
Kim, T.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[24] Pharmacodynamic study of soluble FAS (sFAS) and FASL (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: Results of HCB-05-01 trial
Garcia-Albeniz, X.
Pericay, C.
Alonso, V.
Escudero, P.
Fernandez-Martos, C.
Auge, J.
Gallego, R.
Tosca, M.
Gascon, P.
Maurel, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
Yoshito Komatsu
Chikashi Ishioka
Ken Shimada
Yasuhide Yamada
Makio Gamoh
Atsushi Sato
Tatsuro Yamaguchi
Satoshi Yuki
Satoshi Morita
Shin Takahashi
Rei Goto
Minoru Kurihara
BMC Cancer, 15
[26] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
Komatsu, Yoshito
Ishioka, Chikashi
Shimada, Ken
Yamada, Yasuhide
Gamoh, Makio
Sato, Atsushi
Yamaguchi, Tatsuro
Yuki, Satoshi
Morita, Satoshi
Takahashi, Shin
Goto, Rei
Kurihara, Minoru
BMC CANCER, 2015, 15
[27] Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAFV600E-mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.
Ye, Chen-Yang
Jiao, Xiao-Dong
Liu, Ke
Qin, Bao-Dong
Zhai, Wen-Xin
Yang, Biao-Long
Sun, Li
Dai, Wei-Ping
Ling, Yan
Wu, Ying
Chen, Shi-Qi
Zhang, Ying-Fu
Shi, Dong-Min
Duan, Xiao-Peng
Zhong, Xue
He, Xi
Jia, Cheng-Hao
Zang, Yuan-Sheng
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS316 - TPS316
[28] Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients
Saridaki, Zacharenia
Tzardi, Maria
Papadaki, Chara
Sfakianaki, Maria
Pega, Fraga
Kalikaki, Aristea
Tsakalaki, Eleftheria
Trypaki, Maria
Messaritakis, Ippokratis
Stathopoulos, Efstathios
Mavroudis, Dimitris
Georgoulias, Vassilis
Souglakos, John
PLOS ONE, 2011, 6 (01):
[29] First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)
Levi, Francis
Ducreux, Michel
Hebbar, Mohamed
Rougier, Philippe
Focan, C. N. J.
Guimbaud, Rosine
Carvalho, Carlos
Tumolo, Salvatore
Innominato, Pasquale F.
Ajavon, Yves
Castaing, Denis
De Baere, Thierry
Karaboue, Abdoulaye
Lepere, Celine
Boige, Valerie
Proux, Laetitia
Adam, Rene
Bouchahda, Mohamed
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[30] A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
Eng, Cathy
Bessudo, Alberto
Hart, Lowell L.
Severtsev, Aleksey
Gladkov, Oleg
Mueller, Lothar
Kopp, Mikhail V.
Vladimirov, Vladimir
Langdon, Robert
Kotiv, Bogdan
Barni, Sandro
Hsu, Ching
Bolotin, Ellen
von Roemeling, Reinhard
Schwartz, Brian
Bendell, Johanna C.
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 177 - 186

← 1 2 3 4 →